A clinical study conducted by Nisman et al. in patient samples determined that increased levels of serum TK1 after first and second rounds of chemotherapy in non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) was indicative of treatment failure and poor overall survival [96]. This evidence concerns the gene TK1 and non-small cell lung carcinoma.